By Benjamin Chiou
Date: Tuesday 31 Dec 2024
(Sharecast News) - Autoimmune disease and cancer treatment developer Sareum has revealed that the commercial licence of its jointly developed SRA737 product has been terminated by a biopharma company in the US.
By Josh White
Date: Monday 16 Sep 2024
(Sharecast News) - Cambridge-based biotechnology firm Sareum Holdings announced on Monday that it has received a notice of allowance from the China National Intellectual Property Administration for its patent application concerning crystalline forms of SDC-1801.
By Josh White
Date: Monday 01 Jul 2024
(Sharecast News) - Sareum Holdings announced positive topline results from its phase 1a clinical trial of SDC-1801, a dual TYK2/JAK1 kinase inhibitor under development for treating autoimmune diseases.
Currency | UK Pounds |
Share Price | 13.00p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 45.20 |
52 Week Low | 10.25 |
Volume | 385,918 |
Shares Issued | 133.49m |
Market Cap | £17.35m |
RiskGrade | 594 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth | ![]() |
---|
No dividends found |
Time | Volume / Share Price |
14:06 | 530 @ 13.30p |
13:57 | 18,897 @ 13.17p |
13:55 | 2,823 @ 12.81p |
13:26 | 5,529 @ 12.76p |
13:26 | 2,913 @ 12.76p |
You are here: research